Ultragenyx Pharmaceutical Inc. Balance Sheet
RARE / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
Ultragenyx Pharmaceutical Inc. had $1.5B in total assets with negative shareholders' equity of $80M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $713.5M | $433.6M | $113.4M | $113.4M | $161.1M | $24.3M | $93.6M | $24.3M | $7.4M | $86.2M |
| Accounts Receivable | $158.0M | $122.0M | $73.4M | $40.4M | $28.4M | $23.1M | $32.8M | $12.7M | $5.2M | - | - | - | - | - |
| Inventory | $52.0M | $45.0M | $34.0M | $26.8M | $16.2M | $13.0M | $11.5M | $7.1M | $757.0K | - | - | - | - | - |
| Current Assets | $951.0M | $817.0M | $732.2M | $883.9M | $856.6M | $1.3B | $851.0M | $522.4M | $269.6M | $401.7M | $450.2M | $193.4M | $55.2M | - |
| PP&E (Net) | $244.0M | $266.0M | $290.6M | $259.7M | $141.2M | $73.5M | $44.3M | $20.0M | $21.8M | $17.1M | $7.4M | $3.0M | $1.3M | - |
| Goodwill | $44.0M | $44.0M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | - | - | - | - | - |
| Total Assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B | $1.8B | $1.1B | $719.6M | $490.8M | $540.6M | $559.6M | $198.0M | $59.6M | - |
| Current Liabilities | $384.0M | $344.0M | $280.4M | $261.2M | $181.4M | $189.6M | $103.3M | $74.7M | $71.0M | $60.3M | $27.9M | $12.5M | $5.9M | - |
| Shareholders' Equity | -$80.0M | $255.0M | $275.0M | $352.0M | $653.8M | $608.9M | $383.5M | $608.9M | $531.1M | $184.9M | $531.1M | $184.9M | -$74.8M | -$27.0M |